Author:
Stummann Tina C.,Beilmann Mario,Duker Göran,Dumotier Berengere,Fredriksson J. Magnus,Jones Robin L.,Hasiwa Marina,Kang Y. James,Mandenius Carl-Fredrik,Meyer Thomas,Minotti Giorgio,Valentin Y. Jean-Pierre,Zünkler Bernd J.,Bremer Susanne
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference124 articles.
1. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug discovery, 3, 711–715.
2. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287, 2215–2220.
3. Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discovery Today, 2(9), 436–444.
4. Redfern, W. S., Wakefield, I. D., Prior, H., Pollard, C. E., Hammond, T. G., & Valentin, J. P. (2002). Safety pharmacology—a progressive approach. Fundamental & Clinical Pharmacology, 16, 161–173.
5. Stephens, M. D. B. (2004). Stephens’ detection of new adverse drug reactions. In J. Talbot & P. Waller (Eds.) (5th ed.). Malden, MA, USA: Wiley InterScience.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献